ArticleJournal of the European Academy of Dermatology and Venereology : JEADV2016

Biomodulatory metronomic therapy in stage IV melanoma is well-tolerated and may induce prolonged progression-free survival, a phase I trial.

C Hart et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.